Q3-osavuosiraportti
17 päivää sitten‧47 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
67 287
Myynti
Määrä
68 753
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 355 | - | - | ||
| 178 | - | - | ||
| 94 | - | - | ||
| 91 | - | - | ||
| 340 | - | - |
Ylin
26,96VWAP
Alin
25,82VaihtoMäärä
14,6 553 794
VWAP
Ylin
26,96Alin
25,82VaihtoMäärä
14,6 553 794
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 30.10. | |
| 2025 Ylimääräinen yhtiökokous | 2.9. | |
| 2025 Q2-osavuosiraportti | 17.7. | |
| 2024 Yhtiökokous | 25.6. | |
| 2025 Q1-osavuosiraportti | 24.4. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
12.11.12.11.Tämä julkaisu on poistettu.
·12.11.He seems to be quite a bit in the red on it, so probably not very positive 😊 Definitely believe in it, otherwise one wouldn't have bought in. Everyone knows that biopharma goes up up and down, and sometimes very much up and down 🫣 I've burned myself sometimes, but mostly I've been lucky. Hope one day to find the stock that only goes the right way, but that's probably impossible 😂
·10.11.Warning for this stock. Imlifidase, which is the company's only product, can be expected to be approved in the USA during first 2 second half of 2026. They have almost 1 billion in costs per year. There will be new share issues for several years to come that will end up at 30 öre (like for Immunovia, another Lund-based company with Danish connections)
·10.11.https://www.hansabiopharma.com/our-science/pipeline/ - if anyone is still reading along. One feels like just muting the person's posts ("mute" - as it's called), but one has to keep an eye on what he writes. He is right, in my opinion, when he assesses the development in Immunovia. But he has no factual basis for putting the two stocks in the same category.·11.11. · MuokattuAgreed - one doesn't really have the energy to go through the pipeline for him - that being said, all biotech stocks can fail - I've had quite a few of those myself and whether Hansa becomes one of them, nobody knows yet. But comparing with Immonovia - which I have also had - makes 0.00 sense- ·10.11.Don't know who Benielsen is acting for but I have informed Polar Capital in London who is the main victim (they took a large part of the new issue) In this mess. They should act via Swedish authorities to crack down on all involved in this.·10.11.My take is that your suspicion seems unfounded - see my questions to you below - and that your post could be price-sensitive. But interesting, if Polar reacts in this matter. Do keep us informed, if that happens. In the meantime, I can see that today's low price has tempted the CFO: https://www.nordnet.dk/markedet/nyheder/30fa0d70-4c1f-4944-bc62-8d58bfa72f30 I myself also couldn't resist buying more today.
- ·10.11.I now hope that the authorities look into the trading on September 25th in this stock. And which actors drove up the stock price by over 40 % in 2 weeks at the end of September to be able to carry out the new issue at 39.50.·10.11.My assessment Monday, September 29, was that the announcements below, which came out the Thursday before, started to affect the market after the weekend - and that some short-sellers perhaps suddenly got busy unwinding and "FOMO'ers" got busy getting in. I can, of course, have assessed incorrectly. But the market's memory is often short - and right now, shorting has picked up again despite announced price targets of 95-100. Please also see my questions to you in the previous post. But here are at least the news items leading up to September 29: "25 Sep. 05:58 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) The specialty pharmaceutical company Hansa Biopharma reached its primary goal in the phase 3 study Confides where imlifidase was evaluated in highly sensitized patients before a kidney transplant. The outcome was statistically significant." AND 25 Sep. 07:31 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) The specialty pharmaceutical company Hansa Biopharma announced on Wednesday evening a positive outcome for the Confides study in phase 3 with imlifidase for desensitization of highly sensitized patients before a kidney transplant. The company has thereby come a step closer to entering a multi-billion market. AND THIS ONE: "This potential is enormous both in Europe and the USA. From my perspective, it's not a question of this not being enough to become cash flow positive," says Renée Aguiar-Lucander to Nyhetsbyrån Direkt and adds that "this at least has the potential for a multi-billion dollar market".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
17 päivää sitten‧47 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 12.11.12.11.Tämä julkaisu on poistettu.·12.11.He seems to be quite a bit in the red on it, so probably not very positive 😊 Definitely believe in it, otherwise one wouldn't have bought in. Everyone knows that biopharma goes up up and down, and sometimes very much up and down 🫣 I've burned myself sometimes, but mostly I've been lucky. Hope one day to find the stock that only goes the right way, but that's probably impossible 😂
- ·10.11.Warning for this stock. Imlifidase, which is the company's only product, can be expected to be approved in the USA during first 2 second half of 2026. They have almost 1 billion in costs per year. There will be new share issues for several years to come that will end up at 30 öre (like for Immunovia, another Lund-based company with Danish connections)·10.11.https://www.hansabiopharma.com/our-science/pipeline/ - if anyone is still reading along. One feels like just muting the person's posts ("mute" - as it's called), but one has to keep an eye on what he writes. He is right, in my opinion, when he assesses the development in Immunovia. But he has no factual basis for putting the two stocks in the same category.·11.11. · MuokattuAgreed - one doesn't really have the energy to go through the pipeline for him - that being said, all biotech stocks can fail - I've had quite a few of those myself and whether Hansa becomes one of them, nobody knows yet. But comparing with Immonovia - which I have also had - makes 0.00 sense
- ·10.11.Don't know who Benielsen is acting for but I have informed Polar Capital in London who is the main victim (they took a large part of the new issue) In this mess. They should act via Swedish authorities to crack down on all involved in this.·10.11.My take is that your suspicion seems unfounded - see my questions to you below - and that your post could be price-sensitive. But interesting, if Polar reacts in this matter. Do keep us informed, if that happens. In the meantime, I can see that today's low price has tempted the CFO: https://www.nordnet.dk/markedet/nyheder/30fa0d70-4c1f-4944-bc62-8d58bfa72f30 I myself also couldn't resist buying more today.
- ·10.11.I now hope that the authorities look into the trading on September 25th in this stock. And which actors drove up the stock price by over 40 % in 2 weeks at the end of September to be able to carry out the new issue at 39.50.·10.11.My assessment Monday, September 29, was that the announcements below, which came out the Thursday before, started to affect the market after the weekend - and that some short-sellers perhaps suddenly got busy unwinding and "FOMO'ers" got busy getting in. I can, of course, have assessed incorrectly. But the market's memory is often short - and right now, shorting has picked up again despite announced price targets of 95-100. Please also see my questions to you in the previous post. But here are at least the news items leading up to September 29: "25 Sep. 05:58 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) The specialty pharmaceutical company Hansa Biopharma reached its primary goal in the phase 3 study Confides where imlifidase was evaluated in highly sensitized patients before a kidney transplant. The outcome was statistically significant." AND 25 Sep. 07:31 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) The specialty pharmaceutical company Hansa Biopharma announced on Wednesday evening a positive outcome for the Confides study in phase 3 with imlifidase for desensitization of highly sensitized patients before a kidney transplant. The company has thereby come a step closer to entering a multi-billion market. AND THIS ONE: "This potential is enormous both in Europe and the USA. From my perspective, it's not a question of this not being enough to become cash flow positive," says Renée Aguiar-Lucander to Nyhetsbyrån Direkt and adds that "this at least has the potential for a multi-billion dollar market".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
67 287
Myynti
Määrä
68 753
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 355 | - | - | ||
| 178 | - | - | ||
| 94 | - | - | ||
| 91 | - | - | ||
| 340 | - | - |
Ylin
26,96VWAP
Alin
25,82VaihtoMäärä
14,6 553 794
VWAP
Ylin
26,96Alin
25,82VaihtoMäärä
14,6 553 794
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 30.10. | |
| 2025 Ylimääräinen yhtiökokous | 2.9. | |
| 2025 Q2-osavuosiraportti | 17.7. | |
| 2024 Yhtiökokous | 25.6. | |
| 2025 Q1-osavuosiraportti | 24.4. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
17 päivää sitten‧47 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 30.10. | |
| 2025 Ylimääräinen yhtiökokous | 2.9. | |
| 2025 Q2-osavuosiraportti | 17.7. | |
| 2024 Yhtiökokous | 25.6. | |
| 2025 Q1-osavuosiraportti | 24.4. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 12.11.12.11.Tämä julkaisu on poistettu.·12.11.He seems to be quite a bit in the red on it, so probably not very positive 😊 Definitely believe in it, otherwise one wouldn't have bought in. Everyone knows that biopharma goes up up and down, and sometimes very much up and down 🫣 I've burned myself sometimes, but mostly I've been lucky. Hope one day to find the stock that only goes the right way, but that's probably impossible 😂
- ·10.11.Warning for this stock. Imlifidase, which is the company's only product, can be expected to be approved in the USA during first 2 second half of 2026. They have almost 1 billion in costs per year. There will be new share issues for several years to come that will end up at 30 öre (like for Immunovia, another Lund-based company with Danish connections)·10.11.https://www.hansabiopharma.com/our-science/pipeline/ - if anyone is still reading along. One feels like just muting the person's posts ("mute" - as it's called), but one has to keep an eye on what he writes. He is right, in my opinion, when he assesses the development in Immunovia. But he has no factual basis for putting the two stocks in the same category.·11.11. · MuokattuAgreed - one doesn't really have the energy to go through the pipeline for him - that being said, all biotech stocks can fail - I've had quite a few of those myself and whether Hansa becomes one of them, nobody knows yet. But comparing with Immonovia - which I have also had - makes 0.00 sense
- ·10.11.Don't know who Benielsen is acting for but I have informed Polar Capital in London who is the main victim (they took a large part of the new issue) In this mess. They should act via Swedish authorities to crack down on all involved in this.·10.11.My take is that your suspicion seems unfounded - see my questions to you below - and that your post could be price-sensitive. But interesting, if Polar reacts in this matter. Do keep us informed, if that happens. In the meantime, I can see that today's low price has tempted the CFO: https://www.nordnet.dk/markedet/nyheder/30fa0d70-4c1f-4944-bc62-8d58bfa72f30 I myself also couldn't resist buying more today.
- ·10.11.I now hope that the authorities look into the trading on September 25th in this stock. And which actors drove up the stock price by over 40 % in 2 weeks at the end of September to be able to carry out the new issue at 39.50.·10.11.My assessment Monday, September 29, was that the announcements below, which came out the Thursday before, started to affect the market after the weekend - and that some short-sellers perhaps suddenly got busy unwinding and "FOMO'ers" got busy getting in. I can, of course, have assessed incorrectly. But the market's memory is often short - and right now, shorting has picked up again despite announced price targets of 95-100. Please also see my questions to you in the previous post. But here are at least the news items leading up to September 29: "25 Sep. 05:58 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) The specialty pharmaceutical company Hansa Biopharma reached its primary goal in the phase 3 study Confides where imlifidase was evaluated in highly sensitized patients before a kidney transplant. The outcome was statistically significant." AND 25 Sep. 07:31 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) The specialty pharmaceutical company Hansa Biopharma announced on Wednesday evening a positive outcome for the Confides study in phase 3 with imlifidase for desensitization of highly sensitized patients before a kidney transplant. The company has thereby come a step closer to entering a multi-billion market. AND THIS ONE: "This potential is enormous both in Europe and the USA. From my perspective, it's not a question of this not being enough to become cash flow positive," says Renée Aguiar-Lucander to Nyhetsbyrån Direkt and adds that "this at least has the potential for a multi-billion dollar market".
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
67 287
Myynti
Määrä
68 753
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 355 | - | - | ||
| 178 | - | - | ||
| 94 | - | - | ||
| 91 | - | - | ||
| 340 | - | - |
Ylin
26,96VWAP
Alin
25,82VaihtoMäärä
14,6 553 794
VWAP
Ylin
26,96Alin
25,82VaihtoMäärä
14,6 553 794
Välittäjätilasto
Dataa ei löytynyt